Aclaris Therapeutics (NASDAQ:ACRS) will release its earnings data after the market closes on Tuesday, November 6th. Analysts expect Aclaris Therapeutics to post earnings of ($1.25) per share for the quarter.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The firm had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.76 million. On average, analysts expect Aclaris Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Shares of NASDAQ ACRS opened at $12.22 on Friday. Aclaris Therapeutics has a fifty-two week low of $11.00 and a fifty-two week high of $26.25.
In other news, Director Stephen A. Tullman acquired 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The shares were bought at an average price of $15.97 per share, with a total value of $99,812.50. Following the completion of the purchase, the director now directly owns 163,757 shares in the company, valued at $2,615,199.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen A. Tullman bought 6,600 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were bought at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the transaction, the director now directly owns 170,357 shares in the company, valued at approximately $2,555,355. The disclosure for this purchase can be found here. In the last three months, insiders purchased 392,043 shares of company stock worth $4,298,212. 17.00% of the stock is owned by insiders.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Read More: How a Put Option Works
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.